SEC Filing Summary: ChromaDex Corporation (Form 8-K)
Business Context and Reporting Period
This Form 8-K was filed by ChromaDex Corporation on May 24, 2010, reporting events from its annual meeting of stockholders held on May 20, 2010. The filing details the final voting results for matters submitted to shareholders. Note: The input metadata references "Niagen Bioscience, Inc.," but the filing text explicitly identifies the registrant as ChromaDex Corporation.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity figures. This report focuses exclusively on corporate governance voting outcomes.
Material Changes and Voting Results
Shareholders approved four key proposals at the annual meeting:
- Director Elections: Seven directors were elected unanimously with 21,325,624 votes "For" and 0 "Withheld" for each nominee (Stephen Block, Reid Dabney, Hugh Dunkerley, Mark S. Germain, Frank L. Jaksch, Jr., Kevin M. Jaksch, and Thomas C. Varvaro).
- Authorized Share Increase: An amendment to increase authorized common stock from 50,000,000 to 150,000,000 shares was approved with 21,141,802 votes "For" and 183,822 "Against."
- Equity Incentive Plan Amendment: An amendment to the 2007 Equity Incentive Plan to increase reserved shares to 20% of issued and outstanding stock was approved with 20,903,697 votes "For," 183,822 "Against," and 238,105 "Abstain."
- Auditor Ratification: The appointment of McGladrey & Pullen, LLP as the independent registered public accounting firm for the fiscal year ending January 1, 2011, was ratified with 21,087,519 votes "For" and 238,105 "Abstain."
Guidance, Outlook, and Risks
The filing text does not contain management commentary, financial guidance, outlook, or specific risk factors beyond the standard disclosure of voting results.
Investor Verification Checklist
- Verify the company name discrepancy between the metadata (Niagen Bioscience) and the filing (ChromaDex Corporation).
- Confirm the impact of the 150,000,000 authorized share cap on future dilution potential.
- Review the definitive proxy statement filed on May 4, 2010, for detailed biographies of the elected directors and specifics of the equity plan amendment.
- Check subsequent filings for the actual issuance of shares under the amended equity incentive plan.